![OIG Sounds the Warning on Overbilling of G0483 Definitive Drug Tests](https://www.g2intelligence.com/wp-content/uploads/2023/03/March6-2023.News_.DrugTestingOverpayments-iStock-1800x1250-1-1080x675.jpg)
OIG Sounds the Warning on Overbilling of G0483 Definitive Drug Tests
Labs may be billing Medicare for high-reimbursing and medically unnecessary drug tests, according to the OIG.
Labs may be billing Medicare for high-reimbursing and medically unnecessary drug tests, according to the OIG.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
Even though PAMA has slashed reimbursement rates for many tests, overall Medicare Part B spending on lab tests continues to increase.
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.